Faron Pharmaceuticals Oy: Initial positive data from Phase 2 of BEXMAB arvopaperi.fi - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arvopaperi.fi Daily Mail and Mail on Sunday newspapers.
Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs.
Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.